The North America Atrial Fibrillation Market would witness market growth of 4.8% CAGR during the forecast period (2022-2028).
Heart palpitations, dizziness, lightheadedness, shortness of breath, and chest discomfort are examples of symptomatic episodes. Atrial fibrillation is linked to a higher risk of stroke, dementia, and heart failure. It belongs to the category of supraventricular tachycardia. The most frequent modifiable risk factors for AF a, re high blood pressure and valvular heart diseases.
Heart failure, cardiomyopathy, and congenital heart disease are other heart-related risk factors. Traumatic fever is frequently to blame for valvular heart disease in low- and middle-income nations. Risk factors for lung disease include COPD, obesity, and sleep apnea. Additional risk factors include thyrotoxicosis, diabetes mellitus, excessive alcohol use, and cigarette use.
However, none of the aforementioned dangers are present in around 50% of instances. After feeling the pulse, medical experts may suspect AF and confirm the diagnosis by analyzing an electrocardiogram (ECG). Regularly spaced QRS complexes without P waves are indicative of an AF ECG. Making healthy lifestyle adjustments including quitting smoking, increasing physical exercise, and cutting back on alcohol might minimize the likelihood of developing atrial fibrillation and lessen its effects if it does.
In the United States, heart disease remains the major cause of mortality for both sexes and members of the majority of racial and ethnic groups. Every 36 seconds, the cardiovascular disease takes one life in the USA. One in four fatalities in the US is caused by heart disease, which affects around 659,000 individuals annually. Between 2016 and 2017, the US spent roughly $363 billion on heart disease.
The US market dominated the North America Atrial Fibrillation Market by Country in 2021; thereby, achieving a market value of $677.3 million by 2028. The Canada market is experiencing a CAGR of 6.8% during (2022 - 2028). Additionally, The Mexico market would witness a CAGR of 6.6% during (2022 - 2028).
Based on End User, the market is segmented into Hospitals, Specialty Clinics, and Others. Based on Type, the market is segmented into Surgical and Non-Surgical. Based on Technology, the market is segmented into Radiofrequency, Laser, Cryotherapy, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Global Atrial Fibrillation Market is Estimated to reach $2.7 Billion by 2028, at a CAGR of 9.5%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Johnson & Johnson, MicroPort Scientific Corporation, Boston Scientific Corporation, Abbott Laboratories, Medtronic PLC, BIOTRONIK SE & Co. KG, Koninklijke Philips N.V., Siemens Healthineers AG (Siemens AG) and AtriCure, Inc.
By End User
By Type
By Technology
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
